SMO and meningioma: Among meningiomas with intact NF2, recurrent alterations in several well-established neoplasia genes (such as AKT1, PIK3CA, SMARCE1, and SMO) account for less than 20% of cases11–13, and ongoing clinical trials are investigating the use of relevant precision therapies.